Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

CREB-activity and nmnat2 transcription are down-regulated prior to neurodegeneration, while NMNAT2 over-expression is neuroprotective, in a mouse model of human tauopathy.

Ljungberg MC, Ali YO, Zhu J, Wu CS, Oka K, Zhai RG, Lu HC.

Hum Mol Genet. 2012 Jan 15;21(2):251-67. doi: 10.1093/hmg/ddr492. Epub 2011 Oct 25.

2.

Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L).

Ramsden M, Kotilinek L, Forster C, Paulson J, McGowan E, SantaCruz K, Guimaraes A, Yue M, Lewis J, Carlson G, Hutton M, Ashe KH.

J Neurosci. 2005 Nov 16;25(46):10637-47.

3.

NMNAT suppresses tau-induced neurodegeneration by promoting clearance of hyperphosphorylated tau oligomers in a Drosophila model of tauopathy.

Ali YO, Ruan K, Zhai RG.

Hum Mol Genet. 2012 Jan 15;21(2):237-50. doi: 10.1093/hmg/ddr449. Epub 2011 Sep 30.

4.

Adult-onset focal expression of mutated human tau in the hippocampus impairs spatial working memory of rats.

Mustroph ML, King MA, Klein RL, Ramirez JJ.

Behav Brain Res. 2012 Jul 15;233(1):141-8. doi: 10.1016/j.bbr.2012.04.034. Epub 2012 Apr 25.

5.

In vivo axonal transport deficits in a mouse model of fronto-temporal dementia.

Majid T, Ali YO, Venkitaramani DV, Jang MK, Lu HC, Pautler RG.

Neuroimage Clin. 2014 Mar 31;4:711-7. doi: 10.1016/j.nicl.2014.02.005. eCollection 2014.

6.

A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.

Rosenmann H, Grigoriadis N, Eldar-Levy H, Avital A, Rozenstein L, Touloumi O, Behar L, Ben-Hur T, Avraham Y, Berry E, Segal M, Ginzburg I, Abramsky O.

Exp Neurol. 2008 Jul;212(1):71-84. doi: 10.1016/j.expneurol.2008.03.007. Epub 2008 Mar 21.

PMID:
18490011
7.

Nmnat2 attenuates Tau phosphorylation through activation of PP2A.

Cheng XS, Zhao KP, Jiang X, Du LL, Li XH, Ma ZW, Yao J, Luo Y, Duan DX, Wang JZ, Zhou XW.

J Alzheimers Dis. 2013;36(1):185-95. doi: 10.3233/JAD-122173.

PMID:
23579329
8.

Accumulation of pathological tau species and memory loss in a conditional model of tauopathy.

Berger Z, Roder H, Hanna A, Carlson A, Rangachari V, Yue M, Wszolek Z, Ashe K, Knight J, Dickson D, Andorfer C, Rosenberry TL, Lewis J, Hutton M, Janus C.

J Neurosci. 2007 Apr 4;27(14):3650-62.

9.

Analysis of tau post-translational modifications in rTg4510 mice, a model of tau pathology.

Song L, Lu SX, Ouyang X, Melchor J, Lee J, Terracina G, Wang X, Hyde L, Hess JF, Parker EM, Zhang L.

Mol Neurodegener. 2015 Mar 26;10:14. doi: 10.1186/s13024-015-0011-1.

10.

Effects of the C57BL/6 strain background on tauopathy progression in the rTg4510 mouse model.

Bailey RM, Howard J, Knight J, Sahara N, Dickson DW, Lewis J.

Mol Neurodegener. 2014 Jan 15;9:8. doi: 10.1186/1750-1326-9-8.

11.

In vivo functional brain mapping in a conditional mouse model of human tauopathy (tauP301L) reveals reduced neural activity in memory formation structures.

Perez PD, Hall G, Kimura T, Ren Y, Bailey RM, Lewis J, Febo M, Sahara N.

Mol Neurodegener. 2013 Feb 4;8:9. doi: 10.1186/1750-1326-8-9.

12.

Improved long-term potentiation and memory in young tau-P301L transgenic mice before onset of hyperphosphorylation and tauopathy.

Boekhoorn K, Terwel D, Biemans B, Borghgraef P, Wiegert O, Ramakers GJ, de Vos K, Krugers H, Tomiyama T, Mori H, Joels M, van Leuven F, Lucassen PJ.

J Neurosci. 2006 Mar 29;26(13):3514-23.

13.

TOC1: a valuable tool in assessing disease progression in the rTg4510 mouse model of tauopathy.

Ward SM, Himmelstein DS, Ren Y, Fu Y, Yu XW, Roberts K, Binder LI, Sahara N.

Neurobiol Dis. 2014 Jul;67:37-48. doi: 10.1016/j.nbd.2014.03.002. Epub 2014 Mar 12.

14.

Early depletion of CA1 neurons and late neurodegeneration in a mouse tauopathy model.

Helboe L, Egebjerg J, Barkholt P, Volbracht C.

Brain Res. 2017 Apr 11. pii: S0006-8993(17)30156-7. doi: 10.1016/j.brainres.2017.04.002. [Epub ahead of print]

PMID:
28411086
15.

Soluble tau species, not neurofibrillary aggregates, disrupt neural system integration in a tau transgenic model.

Fox LM, William CM, Adamowicz DH, Pitstick R, Carlson GA, Spires-Jones TL, Hyman BT.

J Neuropathol Exp Neurol. 2011 Jul;70(7):588-95. doi: 10.1097/NEN.0b013e318220a658.

16.

Progressive functional impairments of hippocampal neurons in a tauopathy mouse model.

Ciupek SM, Cheng J, Ali YO, Lu HC, Ji D.

J Neurosci. 2015 May 27;35(21):8118-31. doi: 10.1523/JNEUROSCI.3130-14.2015.

17.

Hyperactivity with Agitative-Like Behavior in a Mouse Tauopathy Model.

Jul P, Volbracht C, de Jong IE, Helboe L, Elvang AB, Pedersen JT.

J Alzheimers Dis. 2016;49(3):783-95. doi: 10.3233/JAD-150292.

PMID:
26519432
18.

Changed conformation of mutant Tau-P301L underlies the moribund tauopathy, absent in progressive, nonlethal axonopathy of Tau-4R/2N transgenic mice.

Terwel D, Lasrado R, Snauwaert J, Vandeweert E, Van Haesendonck C, Borghgraef P, Van Leuven F.

J Biol Chem. 2005 Feb 4;280(5):3963-73. Epub 2004 Oct 27.

19.

Impact of Genetic Reduction of NMNAT2 on Chemotherapy-Induced Losses in Cell Viability In Vitro and Peripheral Neuropathy In Vivo.

Slivicki RA, Ali YO, Lu HC, Hohmann AG.

PLoS One. 2016 Jan 25;11(1):e0147620. doi: 10.1371/journal.pone.0147620. eCollection 2016.

20.

Fractalkine overexpression suppresses tau pathology in a mouse model of tauopathy.

Nash KR, Lee DC, Hunt JB Jr, Morganti JM, Selenica ML, Moran P, Reid P, Brownlow M, Guang-Yu Yang C, Savalia M, Gemma C, Bickford PC, Gordon MN, Morgan D.

Neurobiol Aging. 2013 Jun;34(6):1540-8. doi: 10.1016/j.neurobiolaging.2012.12.011. Epub 2013 Jan 16.

PMID:
23332170

Supplemental Content

Support Center